CBL60 Cerebrolysin (60mg)

CBL60 Cerebrolysin is a porcine-derived neurotrophic peptide mixture studied in neurodegenerative and cognitive research models, synthesized and lyophilized in the USA. Each production batch is purified by HPLC and analyzed by mass spectrometry for peptide profile confirmation, with purity above 99% and independent third-party testing certificates available. Supplied for in-vitro laboratory research use only.

CBL60 Cerebrolysin (60mg) is investigated in longevity-oriented research for its influence on cellular energy systems and stress resilience.

Studies of CBL60 Cerebrolysin (60mg) often measure mitochondrial or redox endpoints in cultured models to characterize its research potential.

Researchers evaluating CBL60 Cerebrolysin (60mg) typically combine functional assays with structural verification to support reproducible findings.

Each vial contains lyophilized peptide at the labeled quantity, and wholesale orders are packed in boxes of ten vials at a single per-vial price.

Quality assurance: every batch is purified by reversed-phase high-performance liquid chromatography and identity-confirmed by mass spectrometry, with purity above 99%. Lot-specific certificates of analysis are available on request. Store lyophilized vials at -20°C, protected from light and moisture; reconstitute with bacteriostatic water immediately before use and avoid repeated freeze-thaw cycles. For in-vitro laboratory research use only — not for human or veterinary use.

Research & Literature

The following peer-reviewed studies and reference documents are commonly consulted by researchers working with CBL60 Cerebrolysin (60mg). Summaries are provided for orientation only and reflect the cited sources.

Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial^[1] — This randomized, placebo-controlled, double-blinded multicenter trial evaluated the efficacy and safety of Cerebrolysin administered during early recovery after acute ischemic stroke. The authors reported improvements in neurological outcomes with Cerebrolysin compared with placebo. The results support Cerebrolysin as an adjunctive treatment in early post-stroke recovery. (Journal of Medicine and Life 2017)

Cerebrolysin and early neurorehabilitation in patients with acute ischemic stroke: a prospective, randomized, placebo-controlled clinical study^[2] — This prospective, randomized, placebo-controlled study evaluated Cerebrolysin combined with early neurorehabilitation in patients with acute ischemic stroke. The authors reported better functional recovery in the Cerebrolysin group. The findings suggest that adding Cerebrolysin to structured rehabilitation may enhance post-stroke outcomes. (Journal of Medicine and Life 2017)

Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke^[3] — This study evaluated Cerebrolysin combined with rehabilitation in patients with severe motor impairment after stroke. The authors reported enhanced motor recovery in the group receiving Cerebrolysin alongside rehabilitation. The results indicate potential benefit of Cerebrolysin in severe post-stroke motor recovery. (BMC Neurology 2016)

References

1. Gharagozli K, Harandi AA, Houshmand S, Akbari N, Muresanu DF, Vester J, Winter S, Moessler H. "Efficacy and safety of Cerebrolysin treatment in early recovery after acute ischemic stroke: a randomized, placebo-controlled, double-blinded, multicenter clinical trial." Journal of Medicine and Life. 2017. pubmed.ncbi.nlm.nih.gov/29075343/
2. Stan A, Birle C, Blesneag A, Iancu M. "Cerebrolysin and early neurorehabilitation in patients with acute ischemic stroke: a prospective, randomized, placebo-controlled clinical study." Journal of Medicine and Life. 2017. pubmed.ncbi.nlm.nih.gov/29362596/
3. Chang WH, Park CH, Kim DY, et al.. "Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke." BMC Neurology. 2016. pubmed.ncbi.nlm.nih.gov/26934986/

All products are supplied as lyophilized powder for in-vitro laboratory research use only and are not for human or veterinary use.